Neurogene, Inc. (NGNE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$38.60+2.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NGNE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -27.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NGNE — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition On August 11, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.…
Why it matters: Updates on cash will show financial health. This helps fund operations until early 2028.
Worry ifCash is more than $243 million. This will support operations until early 2028.
Less concerning ifCash falls below $200 million, which raises concerns about funding.
Why it matters: Operating losses are going up. This affects cash management and investor trust.
Worry ifOperating losses in Q2 report are less than -$33.3M.
Less concerning ifOperating losses in Q2 report exceed -$33.3M.
Why it matters: Updates on cash will show financial health and how well operations can be funded. This is important for clinical trials and development.
Watch forCash reserves remain above $200 million after the debt issuance.
Also watch forCash reserves are below $200 million. This shows financial trouble.
Why it matters: Finishing dosing is important for getting results. It shows progress in clinical work.
Supportive ifDosing in the Embolden trial is done with 25 participants.
Worry ifDosing completion is delayed beyond Q2 2026.
Why it matters: Ongoing safety data will show if NGN-401 is safe. This is key for investor trust.
Watch forThe latest safety update reported no new serious side effects from the treatment.
Also watch forNew serious side effects from the treatment were reported. This raises safety concerns.
Why it matters: Advancing clinical programs is key for growth. Progress shows possible future revenue.
Supportive ifManagement will start a new clinical trial in Q2 2026.
Worry ifNo updates on clinical programs in Q2 2026.
Why it matters: If healthcare revenue growth picks up, it may help Neurogene's market position.
Supportive ifHealthcare revenue growth rises above 10% year over year.
Worry ifHealthcare revenue growth is slowing down and is below 10% year over year.
Why it matters: Completing PPQ runs is key for the BLA submission. Delays could push back timelines.
Supportive ifPPQ runs are completed and reported on time.
Worry ifPPQ runs are delayed beyond the end of 2026.
Why it matters: Updates on cash runway show financial health. They also show the ability to fund operations until 2029.
Supportive ifCash runway extended into Q1 2029 after PPQ completion.
Worry ifCash runway is shortened or not extended after PPQ completion.
Why it matters: Topline data will show the effectiveness of NGN-401 for Rett syndrome. This is crucial for future approvals.
Supportive ifTopline data shows at least 33% of participants improved in the trial.
Worry ifTopline data shows less than 33% of participants improved.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$258 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $775 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,237 loss on $10,000 · 52.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.